Genmab — Marts 2020
-
-
Det største problem med Sanofi er, at pt sælger Genmab mest med Daratumumab i kombination med POM-DEX, så det er lidt samme patientgrundlag. Tilsyneladende er denne kombi ogås meget brugt i anden linie, så spørgsmålet er om Sanofi også kan vinde indpas der med en lavere prissætning. Lad os håbe at sc dosering er en game changer som Jan siger - omvendt kan Sanofi indpas gøre det svært for JNJ at hæve prisen pt.
-
-
I agreed E L.
-
-
Har Karyopharm - spændende hvor markedet reagrer ovenpå den stigning i går. Og så LIGE efter melder ud at de skal hente penge... Smart timing
-
-
The U.S. list price (wholesale acquisition cost, or WAC) for Sarclisa is $650 per 100 mg vial and $3,250 per 500 mg vial. For a typical patient in the U.S., between 70-80 kg (154-176 lbs), this correlates to a cost of $5,200 per infusion. Actual costs to patients are generally anticipated to be lower as the list price does not reflect insurance coverage, copay support, or financial assistance from patient support programs.
-
Analytiker: Genmab skal ikke frygte Sanofi-udfordring
Umiddelbart kunne det lyde som om en dårlig nyhed for Genmab, at Sanofi har fået godkendt en konkurrent til Darzalex, men ifølge analytiker Søren Løntoft Hansen fra Sydbank er Sarclisa næppe en trussel mod Darzalex' dominans.
(medwatch.dk)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind